PALISADE BIO, INC. Retained Earnings
PALISADE BIO, INC. (PALI) had Retained Earnings of $141.00 million as of 2025-06-30, per its 10-Q filed 2025-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2025-08-11
- 2025-06-30: Retained Earnings (Accumulated Deficit) $141.00M.
- 2025-03-31: Retained Earnings (Accumulated Deficit) $138.20M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) $135.90M.
- 2024-09-30: Retained Earnings (Accumulated Deficit) $132.60M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2025-06-30 | $141.00M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $138.20M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $135.90M 10-K · filed 2025-03-24 | |
| 2024-09-30 | $132.60M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | -$129.10M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | -$125.00M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $121.50M 10-K · filed 2024-03-26 | |
| 2023-09-30 | $118.50M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $114.90M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $111.50M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $109.20M 10-K · filed 2023-03-22 | |
| 2022-09-30 | $105.20M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $101.20M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $98.80M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $94.60M 10-K · filed 2022-03-17 | |
| 2021-09-30 | -$95.72M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$103.80M 10-Q · filed 2021-08-23 | |
| 2021-03-31 | -$240.53M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | -$68.03M 10-Q · filed 2021-11-12 | -$238.24M 10-K · filed 2021-03-22 |
| 2020-09-30 | -$233.82M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | -$231.50M 10-Q · filed 2020-08-13 | |
| 2020-03-31 | -$229.55M 10-Q · filed 2020-05-15 | |
| 2019-12-31 | -$221.98M 10-K · filed 2021-03-22 | |
| 2019-09-30 | -$219.94M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | -$218.17M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | -$216.74M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | -$213.62M 10-K · filed 2020-03-27 | |
| 2018-09-30 | -$213.30M 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$211.47M 10-Q · filed 2018-08-13 | |
| 2018-03-31 | -$210.85M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | -$208.70M 10-K · filed 2019-03-22 | |
| 2017-09-30 | -$205.38M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | -$205.25M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | -$200.60M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | -$193.03M 10-K · filed 2018-04-02 | |
| 2016-09-30 | -$187.64M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | -$182.42M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | -$178.56M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | -$171.96M 10-K · filed 2017-03-23 | |
| 2015-09-30 | -$167.19M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | -$161.56M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | -$156.11M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | -$151.05M 10-K · filed 2016-03-14 | |
| 2014-09-30 | -$145.55M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | -$141.10M 10-Q · filed 2014-08-08 | |
| 2014-03-31 | -$134.35M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$128.43M 10-K · filed 2015-03-16 | |
| 2013-09-30 | -$125.12M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | -$118.44M 10-Q · filed 2013-08-08 | |
| 2013-03-31 | -$112.18M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | -$108.59M 10-K · filed 2014-03-10 | |
| 2012-09-30 | -$105.88M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | -$103.30M 10-Q · filed 2012-08-09 | |
| 2012-03-31 | -$100.93M 10-Q · filed 2012-05-09 | |
| 2011-12-31 | -$98.47M 10-K · filed 2013-03-15 | |
| 2011-09-30 | -$95.92M 10-Q · filed 2011-11-09 | |
| 2011-06-30 | -$92.70M 10-Q/A · filed 2011-09-23 | |
| 2010-12-31 | -$85.95M 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |